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At sites of inflammation, certain regulatory T cells
(Treg cells) can undergo rapid reprogramming into
helper-like cells without loss of the transcription
factor Foxp3. We show that reprogramming is
controlled by downregulation of the transcription
factor Eos (Ikzf4), an obligate corepressor for
Foxp3. Reprogramming was restricted to a specific
subset of ‘‘Eos-labile’’ Treg cells that was present
in the thymus and identifiable by characteristic
surface markers and DNA methylation. Mice made
deficient in this subset became impaired in their
ability to provide help for presentation of new anti-
gens to naive T cells. Downregulation of Eos required
the proinflammatory cytokine interleukin-6 (IL-6), and
mice lacking IL-6 had impaired development and
function of the Eos-labile subset. Conversely, the
immunoregulatory enzyme IDO blocked loss of
Eos and prevented the Eos-labile Treg cells from re-
programming. Thus, the Foxp3+ lineage contains
a committed subset of Treg cells capable of rapid
conversion into biologically important helper cells.
INTRODUCTION
Foxp3+ regulatory T cells (Treg cells) are essential to maintain
self-tolerance. However, some Treg cells also retain a degree
of plasticity and under certain conditions may change (‘‘repro-
gram’’) to adopt a proinflammatory phenotype (da Silva Martins
and Piccirillo, 2012). This has been observed under conditions
including lymphopenia (Komatsu et al., 2009; Yurchenko et al.,
2012), autoimmunity (Zhou et al., 2009), and sepsis (Oldenhove
et al., 2009). Because these are pathologic conditions, it has
been somewhat controversial whether Treg reprogramming is
a rare and abnormal occurrence or a normal part of Treg cell998 Immunity 38, 998–1012, May 23, 2013 ª2013 Elsevier Inc.biology. Recently, emerging studies suggest that destabilization
of the Treg cell phenotype is a real phenomenon and can have a
major impact on the course of inflammatory responses in vivo
(Laurence et al., 2012).
Under most circumstances, the role of Foxp3+ Treg cells is
clearly suppressive (Kim et al., 2007). However, in certain set-
tings, Treg cells may adopt a paradoxical ‘‘helper-like’’ role:
this includes contexts as diverse as vaccination (Vendetti et al.,
2010), tumors (Addey et al., 2011), graft rejection (Vokaer et al.,
2010), and T helper 2 (Th2) cell responses (Tsuji et al., 2009;
Wang et al., 2010). In most of these studies the ‘‘helper-like’’
Treg cells appeared to have lost Foxp3. However, this finding
would seem to be at odds with studies suggesting that Foxp3
expression is highly stable in Treg cells once established (Miyao
et al., 2012; Rubtsov et al., 2010). Thus, there has been some
controversy over whether fully-committed Foxp3-lineage Treg
cells ever transform into helper cells.
In the current study, we asked whether inducible transforma-
tion into helper cells might in fact be a natural property of certain
Foxp3+ cells—not as a loss of lineage fidelity, but as a normal
role that some Treg cells inherently adopt under specific circum-
stances. This hypothesis arose from our previous observation
that when Treg cells enter an inflammatory milieu, such as lymph
nodes (LNs) draining a site of vaccination, some of them can
rapidly convert into a proinflammatory phenotype, while still
expressing Foxp3 (Sharma et al., 2010; Sharma et al., 2009).
These reprogrammed Treg cells were found to play an important
functional role in licensing DCs to present new antigens in naive
hosts (Sharma et al., 2010).
However, these observations raised a paradox: because re-
programmed Treg cells continued to express Foxp3, how were
they able to express proinflammatory genes that are normally
repressed by Foxp3? In the current study, we show that this
phenotypic transformation is controlled by the corepressor Eos
(Ikzf4). Eos is a member of the Ikaros family of transcription
factors that also includes Aiolos and Helios (Quintana et al.,
2012; Thornton et al., 2010). Eos forms a complex with Foxp3
and is required in order for Foxp3 to inhibit its downstream target
genes and maintain the suppressive Treg cell phenotype
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rather than loss of Foxp3, underlies rapid reprogramming of
Treg cells in response to inflammation, and we identify a subset
of Foxp3+ Treg cells that are constitutively committed to loss of
Eos under specific inflammatory conditions.
RESULTS
Foxp3 Is Stable in Reprogrammed Treg Cells,
but Eos Is Downregulated
To create local inflammation, we treated mice with CD8+ OT-I
T cells specific for ovalbumin (OVA) followed by vaccination
with whole OVA protein in incomplete Freund’s adjuvant (IFA)
plus the TLR9 ligand CpG. Four days later, Treg cells in
vaccine-draining lymph nodes (VDLNs) were analyzed by flow
cytometry for expression of Eos. Validation of intracellular
Eos staining is shown in Figure S1A available online. As
markers of reprogramming, Treg cells were stained for inter-
leukin-2 (IL-2), IL-17, and cell-surface CD40L. As controls,
distant LNs, not draining the vaccination site, were taken
from the same mouse. To identify Treg cells, we used host
mice bearing either a Foxp3-GFP reporter knock-in (Foxp3GFP
mice) (Fontenot et al., 2005), or a BAC-transgenic GFP-Cre
reporter under a Foxp3 promoter construct (Zhou et al.,
2009). All experiments were confirmed in both reporter strains
and were further confirmed by using intracellular Foxp3 staining
in wild-type (WT) mice.
Figure 1A shows that in the control (distant) LNs, virtually all
Treg cells expressed Eos, and none expressed detectable
CD40L, IL-2, or IL-17. In contrast, in the inflammatory VDLNs,
a population of Treg cells had lost Eos (arrows), and many of
these had upregulated IL-2, IL-17, and CD40L. In our system,
surface CD40L correlated closely with the reprogrammed
phenotype (Sharma et al., 2010), and was thus a useful marker
for these cells. None of the reprogrammed Treg cells had lost
Foxp3 (left-hand dot plots); rather, it was specifically the loss
of Eos that correlated with the altered phenotype. Figure S1B
shows that loss of Eos was rapid, starting within 6 hr of
vaccination.
Eos was also downregulated in the setting of a mild, nonle-
thal influenza infection (Figure 1B). Many of these Eos-negative
Treg cells upregulated CD40L (arrow) and coexpressed IL-2
and IL-17. Despite reprogramming, Treg cells continued to
express Foxp3. The number of Eos-negative Treg cells during
infection varied but they were not rare, showing that reprog-
ramming could occur under conditions of mild physiologic
inflammation.
Thus, under certain conditions, a population of Treg cells was
able to downregulate expression of the corepressor Eos and
upregulate proinflammatory genes, without loss of Foxp3.
Downregulation of Eos Requires IL-6
To elucidate the pathways driving reprogramming, we used an
in vitro coculture model, as previously described (Sharma
et al., 2010). Resting splenic Treg cells were cocultured with
activated DCs from VDLNs. To recapitulate the inflammatory
milieu, cocultures also received OT-I effector T cells plus
cognate SIINFEKL antigen. Figure 1C shows that after 2 days
in coculture a substantial number of Treg cells had lost Eos,and many of these had upregulated CD40L (middle dot-plots),
but all Treg cells continued to express the Foxp3GFP reporter
(lower dot-plot). In experiments using CFSE-labeled Treg cells
(bottom histogram), reprogramming could occur at a time
when proliferation was still minimal.
In other systems, the proinflammatory cytokine IL-6 has been
shown to drive Treg cell reprogramming (Yang et al., 2008).
When we added neutralizing anti-IL-6 to cocultures (Figure 1C,
right-hand panel), this prevented loss of Eos and blocked func-
tional reprogramming. Consistent with this, when mice lacking
IL-6 (Il6/mice; Kopf et al., 1994) were immunized in vivo, their
Treg cells failed to undergo reprogramming (Figure 1D). Thus,
IL-6 appeared to be an important driver for loss of Eos and
reprogramming.
However, IL-6 did not act in isolation. Adding IL-6 alone to
activated Treg cells did not cause reprogramming (Figure S1C).
Rather, reprogramming required integrated signals from acti-
vated DCs, activated effector cells, and cognate MHC class II
(Figure 1E). If antigen for the OT-I effector T cells was omitted
(Figure 1E, top row) then Treg cell reprogramming could not
occur. One key reason for this was that the activated effector
cells were needed to trigger IL-6 expression by the DCs (Fig-
ure S1E). Further, it was necessary that the DCs be derived
from an activated milieu (e.g., from LNs draining a vaccine site
or tumor) rather than resting DCs (Figure S1E). Finally, reprog-
ramming required cognate interaction between the Treg cells
and activated DCs via MHC class II (Figure 1E, bottom row).
Under all these various conditions, Foxp3 expression remained
unchanged (Figure 1E, left-hand dot-plots; however, for tech-
nical caveats regarding intracellular staining of Foxp3 after
reprogramming, see Figure S1E).
Taken together, these data showed that the combination
of activated DCs, derived from an inflammatory milieu, plus
antigen-activated effector T cells together drove reprogramming
of Treg cells. Under these conditions, IL-6 was a key cytokine
mediating Eos downregulation.
Downregulation of Eos Is Mechanistically Required
in Order for Treg Cells to Undergo Reprogramming
To test the mechanistic role of Eos, we forced overexpression
of Eos in resting Treg cells by retroviral transduction and
asked whether this prevented reprogramming. For transduction
studies, T cells would normally be activated with mitogen,
because retroviruses require host cells to be in cell cycle;
however, a nonspecific mitogen would have completely altered
the physiologic response of resting Treg cells to reprogramming
signals. Therefore, we developed the transduction system
shown in Figure S2, which took advantage of the fact that
many resting Treg cells are already constitutively in cell cycle
without the need for mitogen (O’Gorman et al., 2009).
Resting Treg cells were pre-incubated with bicistronic MSCV-
based retroviral vector overnight in un-activated co-cultures
(i.e., no SIINFEKL peptide). After 24 hr the virus was washed
off and SIINFEKL added to drive reprogramming. Under this
protocol, typically 20%–40% of Treg cells were transduced,
with the transduced Treg cells being specifically those that
were in cell-cycle (Ki67+, as shown in Figure S2). Essentially no
other cells were transduced, since there was no mitogen to drive
their proliferation at the time of virus exposure.Immunity 38, 998–1012, May 23, 2013 ª2013 Elsevier Inc. 999
Figure 1. Treg Cells that Undergo Reprogramming Continue to Express Foxp3 but Downregulate Eos
(A) Foxp3GFP mice received OT-I cells plus vaccination with whole OVA protein + CpG adjuvant in IFA. After 4 days, cells were harvested from VDLNs or control
nondraining LNs from the same mouse and stained as shown. Inset shows the percentage of events in each quadrant.
(B) Foxp3GFP mice were infected intranasally with influenza virus strain X31. After 5 days, mononuclear cells were isolated from lung. Experiments were also
replicated in Bac-transgenic Foxp3GFP-Cre reporter mice (righthand dot-plot).
(legend continued on next page)
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GFP vector and then exposed to reprogramming conditions
underwent extensive loss of Eos, whereas Treg cells transduced
with Eos vector remained >80% Eos+ under the same condi-
tions, with many becoming EosHI. Figure 2B shows that
Treg cells transduced with control vector displayed extensive
phenotypic reprogramming (CD40L, IL-2, IL-17), whereas the
same Treg cells transduced with Eos vector could not repro-
gram, and most retained high surface CTLA-4. In these cultures,
Treg cells with forced overexpression of Eos created a domi-
nantly suppressive milieu that affected all cells in coculture,
so the nontransduced population in those wells did not serve
as a true, independent control. However, the vector-only cocul-
tures were true controls, and in those both transduced and
nontransduced cells underwent reprogramming. Consistent
with the role of IL-6 in driving Eos downregulation, adding high
levels of recombinant IL-6 to cocultures could overcome trans-
duction and force Eos downregulation and reprogramming
(Figure 2C).
Thus, loss of Eos was not simply a passive concomitant of
Treg cell reprogramming but rather was a required mechanism
underlying the switch to a proinflammatory phenotype. This
was consistent with the known role of Eos as a corepressor,
required in order for Foxp3 to silence proinflammatory target
genes (Pan et al., 2009).
Forced Overexpression of Eos Abrogates the Functional
Helper Activity of Reprogrammed Treg Cells
To test the functional helper activity of reprogrammed Treg cells,
we asked whether these cells could rescue the profound helper
defect in mice lacking CD40L (Cd40lg/ mice), as previously
described (Sharma et al., 2010). CD40L is critical in order to
‘‘license’’ DCs, and Cd40lg/ mice are unable to prime naive
CD8+ cells to OVA protein (Grewal et al., 1996). Figure 2D shows
that when CD40L-sufficient WT Treg cells were adoptively
transferred into Cd40lg/ hosts, many of them reprogrammed
following vaccination and upregulated CD40L, and this rescued
the CD8+ response to OVA vaccine (left panels). In contrast,
nonregulatory CD4+ cells were unable to upregulate CD40L
within the course of these assays and could not rescue priming
in Cd40lg/ hosts (right panels).
By using this model, we next asked whether forced overex-
pression of Eos abrogated the ability of Treg cells to function
as helper cells in vivo (Figure 2E). CD4+CD25+ Treg cells were
transduced with Eos vector or control vector as above, then
transferred into Cd40lg/ hosts. Following immunization, Treg
cells transduced with control vector were able to reprogram,
express CD40L, and provide help for OT-I priming. In contrast,
Treg cells transduced with Eos could not upregulate CD40L
and did not provide help for OT-I.(C) In vitro coculture system: activated DCs were sorted from VDLNs 2 days after
Foxp3GFP mice. DCs and Treg cells were combined with additional OT-I cells plus
blocked with neutralizing antibody. Histogram shows Treg cell division from a si
(D) IL-6-deficient (Il6/) mice or WT B6 controls received OT-I cells + OVA
reprogramming on day 4.
(E) Treg cells were sorted from BAC-transgenic Foxp3GFP-Cre mice and used in co
antibody (anti-IAb) as indicated.
Each panel is representative of between three and nine experiments with similarThus, the phenotypic changes mediated by the downregu-
lation of Eos reflected functional helper-cell activity in vivo.
Specifically, the upregulation of CD40L by reprogrammed Treg
cells allowed them to rescue the helper-cell defect in Cd40lg/
hosts.
Identification of a Specific Subset of Treg Cells
with Labile Eos Expression
We noted that only a subset of Treg cells lost Eos and underwent
reprogramming. We therefore asked wether there might be a
specific population of Treg cells in which Eos was inherently
more unstable. As one marker for this instability, we examined
the decay kinetics (half-life) of the Eos protein when new protein
synthesis was blocked by the inhibitor cycloheximide (CHX).
This was a purely biochemical test and did not measure Treg
cell reprogramming itself; rather, the goal was merely to ask
whether Eos was less stable in certain Treg cells than others.
(Likewise, any off-target effects of CHX (Hershko et al., 2004)
were not problematic for the assay, because the goal was simply
to disclose any Treg cells with unstable Eos.) For these studies,
we tested cells from thymus, where the Foxp3+ cells would be
bona fide natural Treg cells. Figure 3A shows that thymic Treg
cells displayed two distinct responses to CHX: most maintained
stable Eos expression, but a subset showed rapid loss of Eos,
with 10-fold decrease within 1 hr. By screening a number of
surface markers, we determined that this ‘‘Eos-labile’’ popula-
tion was identified by expression of CD38, a surface antigen
found on a subset of Treg cells (Fisson et al., 2003) and other
lymphocytes (Figure S3A). The same population also coex-
pressed the activation marker CD69, whereas none of them
expressed the maturation marker CD103. The Eos-labile subset
of Treg cells expressed the same levels of Foxp3 as the Eos-
stable subset (upper dot plots in Figure 3A) and expressed
similar patterns of CD25 and intracellular CTLA-4 (Figure 3B).
In the periphery, similar Eos-labile Treg cells were also found,
with the same phenotype of CD38+CD103NEG, as shown in
Figure S3B.
Taken together, these studies suggested that an identifiable
population of Treg cells, present as early as the thymus
and with a characteristic pattern of cell-surface markers,
displayed an inherently more labile pattern of Eos expres-
sion in vitro. Based on this, we next asked whether these
markers identified the cells that were committed to functional
reprogramming.
The Eos-Labile Phenotype Identifies the Subset of Treg
Cells Capable of Functional Reprogramming
For cell-sorting experiments, we selected the markers CD38+
CD103NEG to enrich for Eos-labile Treg cells, and CD103+
CD38NEG for Eos-stable Treg cells. (Of note, this pattern ofOT-I + vaccination. Resting splenic Treg cells were sorted from unimmunized
SIINFEKL antigen in vitro and cocultured for 2 days. Where indicated, IL-6 was
milar experiment, using B6 Treg cells (CD4+CD25+) labeled with CFSE.
vaccine and then Treg cells (CD4+CD25+) from VDLNs were analyzed for
culture assays as in (C), with or without SIINFEKL peptide and MHC-II blocking
results. See also Figure S1.
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Figure 2. Forced Overexpression of Eos in Treg Cells Prevents Reprogramming
(A–C) Resting B6 Treg cells (CD4+CD25+) were preincubated with retroviral vector (control GFP-only or Eos-GFP) in cocultures as described in Figure S2.
After 24 hr, cocultures were washed free of vector and SIINFEKL was added to trigger reprogramming. Cells were analyzed 2 days later. (A) Expression of Eos
in GFP-expressing (transduced) cells. (B) Markers of reprogramming after transduction. (C) Addition of high-dose IL-6 (50 ng/ml) to cocultures could overcome
Eos transduction and force reprogramming.
(legend continued on next page)
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excluded all double-positive and double-negative Treg cells,
because these were ambiguous; further, the markers became
optimally separated after 1 hr of CHX pretreatment, so this
was used where highest purity was desired. Thymic Treg cells
were sorted into Eos-labile and Eos-stable cohorts and trans-
ferred into new B6 hosts. Recipients received OT-I and vaccine,
then 4 days later the transferred Treg cells were harvested from
VDLNs (Figure 3C). Following vaccination, the transferred Eos-
labile Treg cells lost Eos and underwent reprogramming,
whereas the Eos-stable Treg cells maintained Eos expression
and showed no reprogramming. In both groups the endogenous
host Treg cells underwent reprogramming as expected (data
not shown), so the host milieu for both populations was the
same.
To test for functional helper activity, we used the Cd40lg/
model described in Figure 2. Eos-labile and Eos-stable Foxp3+
populations were sorted from spleen, and each transferred
into Cd40lg/ hosts (Figure 3D). Following immunization, the
Eos-labile Treg cells lost Eos, upregulated CD40L and function-
ally rescued OT-I priming, whereas the Eos-stable Treg cells
maintained Eos expression, did not reprogram, and could not
rescue OT-I.
Thus, in both thymus and periphery, a subset of resting Treg
cells displayed a characteristic pattern of surface markers that
identified them as susceptible to functional reprogramming.
This suggested that the propensity to reprogram reflected
a stable property, established during Treg differentiation.
The Eos-Labile Subset Requires IL-6 for Intrathymic
Development
Based on Figure 1C, above, we knew that IL-6 was an important
driver of functional reprogramming. IL-6 is also constitutively
expressed in the thymus (Yarilin and Belyakov, 2004). Therefore,
we asked whether IL-6 might be involved in the development
of the Eos-labile subset. Figure 3E compares thymic Treg
cells from WT mice versus IL-6 deficient mice (Il6/). Thymus
from Il6/ mice displayed a normal number of Treg cells, but
selectively failed to develop the specific CD38+CD69+ subset
that normally marked the Eos-labile population. Consistent
with this, none of the Treg cells in Il6/ thymus showed labile
Eos expression in the CHX assay (right-hand dot-plots). Further
consistent, when mature splenic Treg cells from Il6/ mice
were tested in reprogramming assays (Figure S3C), none of
them were able to undergo functional reprogramming. This
appeared to reflect an intrinsic defect in Treg cells from Il6/
mice, because all other cells in these cocultures were from
normal WT donors. Taken together, these data suggested that
IL-6 was required for differentiation of the Eos-labile (but not
the Eos-stable) subset of Treg cells. In the absence of IL-6,
the Eos-labile subset selectively failed to develop in thymus
and periphery.(D) Rescue of CD40L-deficient hosts by reprogrammed Tregs. Cd40lg/ hosts
nonregulatory CD4+ cells. Mice then received CFSE-labeled OT-I cells plus OVA
(E) Similar to the preceding panel, but Thy1.1 Treg cells (without transgene, sort
GFP-only vector. Treg cells were recovered by CD4 bead-sorting, transferred in
were dominantly suppressive, it was not necessary to separate them from the un
Each panel is representative of between three and five independent experimentsHelp from Eos-Labile Treg Cells Is Required during
Priming of Naive Mice to New Antigen
To further test whether help from reprogrammed Treg cells
contributed to T cell priming, we used mice in which Treg cells
could be inducibly ablated with diphtheria toxin (DT). This model
allowed Treg cells to be selectively depleted from previously
intact adult mice. However, it had the drawback that mice
rapidly develop autoimmune inflammation when Treg cells are
removed (Kim et al., 2007). Because of this limitation, we used
only short-term readouts and confirmed all results in the com-
plementary Cd40lg/ model. Foxp3GFP-Cre mice were crossed
with a ROSA26lox-stop-loxDTR strain to produce mice expressing
the DT receptor on all cells that had activated the Foxp3
promoter (Sharma et al., 2010). Without Treg cell depletion
(Figure 4A, DT group), OT-I cells activated normally in these
mice, and virtually all of the CD40L-expressing cells in VDLNs
were derived from reprogrammed Treg cells (marked by GFP-
Cre). However, when Treg cells were depleted (+DT group), the
expression of CD40L was markedly reduced during priming,
and OT-I activation was compromised. Thus, consistent with
the findings in the Cd40lg/ model, help from reprogrammed
Treg cells appeared important to support normal priming of
naive CD8+ T cells. Further consistent with theCd40lg/model,
Figure S4A shows that adoptive transfer of the Eos-labile Treg
cell subset (but not the Eos-stable subset) selectively restored
the helper activity lost in DT-treated mice.
We next asked whether the requirement for help from reprog-
rammed Treg cells could be replaced by adding back the
specific molecular signals normally supplied by the depleted
Treg cells. The righthand panels in Figure 4A show that OT-I
response could be fully rescued by treating Treg-depleted
mice with a CD40-activating antibody plus recombinant IL-2
at the time of immunization. (This combination was empirically
identified by screening key factors known to be supplied by
helper T cells.)
One important biologic role of T-helper cells is to activate or
‘‘license’’ DCs (Schoenberger et al., 1998). We therefore tested
the activation status of DCs after vaccination in the presence
or absence of Treg cells. Figure 4B uses CD86 as a representa-
tive DC marker (similar effects were seen with CD80, CD40, and
MHC class II, data not shown). In mice with intact Treg cells,
vaccination produced widespread activation of DCs in VDLNs
as expected. However, when Treg cells were depleted, DC acti-
vation became significantly compromised. DC activation was
fully restored by supplying the artificial rescue cocktail of CD40
agonist antibody + rIL-2. Thus, one important biologic effect
of reprogrammed Treg cells was to help support activation of
resting DCs.
Our system focused on initial priming to a new antigen,
because this was when Treg cells were the most critical (see
Figure S4B). We hypothesized that the priming step might be
particularly dependent on help from Treg cells becausereceived adoptive transfer of CD40L-sufficient Foxp3GFP-Thy1.1 Treg cells or
vaccine as in Figure 1A, and VDLNs analyzed on day 4.
ed CD4+CD25+) were first transduced in vitro with Eos-GFP vector or control
to Cd40lg/ hosts, and immunized. (Because the Eos-transduced Treg cells
transduced Treg cells.)
with similar results. See also Figure S2.
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Figure 3. A Specific Subset of Treg Cells with the Ability to Reprogram Is Identified by Labile Eos Expression at Rest
(A) Thymic cells from Foxp3GFP mice were disaggregated and incubated with cycloheximide (CHX) or vehicle control (‘‘resting’’) for 1 hr in vitro as described in
Supplemental Experimental Procedures, then stained for Eos versus cell-surface markers. Arrows indicate the Eos-labile subset. Panel is representative of 15
similar experiments that used both Foxp3GFP and WT B6 mice.
(B) Resting thymic Treg cells showed similar expression of Foxp3, Eos, intracellular CTLA-4, and surface CD25 between CD38+ (Eos-labile) and CD38NEG
(Eos-stable) subsets.
(legend continued on next page)
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CD4+ cells are slow to activate and do not possess the pre-
formed pool of CD40L found in memory T cells; Koguchi et al.,
2011). To test this hypothesis, we extensively preimmunized
Foxp3GFP-Cre 3 ROSA26lox-stop-loxDTR mice with OVA to create
a preexisting pool of OVA-specificmemoryCD4+ cells. Figure 4C
shows that, in preimmunized mice, help from Treg cells was no
longer needed, and the memory (conventional) CD4+ cells could
now fully support priming of new OT-I cells following DT
depletion.
The preceding studies focused on cross-presentation to
CD8+ T cells, which is known to be helper-dependent. However,
the requirement for reprogrammed Treg cells in order to acti-
vate resting DCs (see Figure 4B, above) suggested that even
CD4+ T cells might require support from reprogrammed Treg
cells. Figure 4D tests this hypothesis by using the Cd40lg/
model. Priming of naive CD4+ effector cells (OT-IIRag2/) was
markedly compromised in the absence of host CD40L, and
activation of DCs was impaired. DC activation was restored
and OT-IIRag2/ proliferation rescued by adoptive transfer of
WT (CD40L-sufficient) Treg cells (lower panels). The depen-
dence of CD4+ OT-IIRag2/ cells on help from Treg cells was
further confirmed by using DTR depletion (Figure S4C).
Taken together, the preceding studies showed that reprog-
rammed Treg cells supplied an important helper activity in the
specialized setting of priming to a new antigen. Analogous
help could be supplied by conventional memory CD4+ T cells,
if available; but in the absence of memory cells, reprogrammed
Treg cells supplied important early help to license DCs and sup-
port T cell priming.
Eos-Labile Cells Are Functionally Suppressive
Treg Cells
Wenext askedwhether theEos-labile subsetwere authentic Treg
cells. Figure 5A shows that resting Eos-labile Treg cells constitu-
tively expressedhigh levels of Foxp3mRNA, similar toEos-stable
Treg cells and much higher than non-Treg cells (Figure 5A). Eos
mRNA was also higher in both of the Treg cell subsets than in
nonregulatory CD4+ cells (the Eos-labile Treg cells expressed
somewhat less Eos mRNA than the Eos-stable cells, which may
be consistent with their more labile Eos expression). Figure S5A
shows that expression of Foxp3 protein was stable in Eos-labile
Treg cells, under both reprogramming and nonreprogramming
conditions, and through multiple rounds of cell division.
Figure 5B shows that Eos-labile Treg cells, sorted directly
ex vivo, mediated functional suppressor activity comparable to
Eos-stable Treg cells. The readout in these studies was a con-
ventional in vitro suppression assay using anti-CD3 mitogen,
so there were no vaccine-activated DCs or other conditions
present to drive reprogramming.(C) Thymic cells from Foxp3GFP-Thy1.1 donors were incubated with CHX for 1 hr
(CD38+CD103NEG) and Eos-stable (CD38NEGCD103+) cohorts and transferred int
day 4. Panel is representative of four experiments.
(D) Splenic Treg cell subsets were sorted as in the previous panel and transferred
were analyzed on day 4. Panel is representative of five experiments.
(E) Thymic cells from IL-6 deficient mice orWT B6 controls were tested in a 4 hr CH
subset. Examples of the Foxp3 gating for each strain are shown at left.
Each panel representative of at least three experiments or as noted. See also FigOne stringent test of Treg cell function is the ability to pro-
tect Rag-deficient hosts from autoimmune colitis caused by
CD45RBHI effector cells. Figure 5C shows that sorted Eos-labile
Treg cells were fully protective in a Rag2/ colitis model. (The
functional separation of the sorted Eos-labile and Eos-stable
subsets is documented in Figure S5B). Despite the lymphopenic
environment, Eos-labile Treg cells showed no loss of Foxp3, no
downregulation of Eos, and no reprogramming in the mesenteric
LNs (Figure 5C dot-plots). Thus, the Eos-labile cells behaved
as authentic Treg cells. However, even while protecting from
colitis in the gut, Eos-labile Treg cells elsewhere in the same
animal could reprogram when challenged with vaccine and
OT-I (Figure 5D, right-hand plots). In contrast, under the same
conditions, the Eos-stable Treg cells showed no reprogramming
in VDLNs (Figure 5D, left plots).
These data show that both Eos-labile and Eos-stable subsets
were fully functional, suppressive Treg cells but that each
retained its characteristic propensity to reprogram or not, even
after a prolonged period in Rag2/ hosts.
Epigenetic Analysis Shows that Eos-Labile Treg Cells
Are Distinct from Eos-Stable Treg Cells
Eos-labile Treg cells appeared durably committed to their re-
programmable phenotype. Such commitment is often reflected
in epigenetic changes. Therefore, we examined genome-wide
DNA methylation patterns (Meissner et al., 2008) asking whether
the Eos-labile Treg cells were identifiably distinct from their
Eos-stable counterparts. Treg cell subsets were isolated from
thymus (natural Treg cells) and spleen (mixture of peripheral
Treg cells); controls were nonregulatory CD4+ cells from spleen.
Figure 6A shows hierarchical clustering analysis of those regions
with statistically significant differences in methylation between
splenic Eos-labile Treg cells and control nonregulatory CD4+
cells. The dendrogram shows that all four Treg cell populations
clustered together. The Eos-stable Treg cells from thymus and
spleen were similar to each other. The Eos-labile Treg cells
were distinct but were closely related to the Eos-stable Treg
cells, as would be expected given their uniform expression of
Treg cell markers (Figure 3B, above) and functional suppressor
activity (Figure 5). To illustrate this shared relationship, we
marked several informative loci on the heatmap in Figure 6A,
defined as genes that were similarly methylated in all the Treg
cell populations, whereas all Treg cell populations were different
from nonregulatory CD4+ cells. The methylation patterns for
several such loci are shown in detail in Figure S6.
Figure 6B shows the lineage-specific TSDR (CNS2) region
of the Foxp3 gene (Zheng et al., 2010). Eos-labile Treg cells
were somewhat less highly demethylated at the TSDR than
the Eos-stable Treg cells, but both showed greater demethyla-
tion than non-Treg cells. Functionally, TSDR demethylation isto improve separation of sorting markers, then Treg cells sorted into Eos-labile
o B6 mice. Mice were challenged with OT-I + vaccine and VDLNs analyzed on
into Cd40lg/ hosts. Mice received CFSE-labeled OT-I + vaccine, and VDLNs
X assay, then stained for CD38 and CD69 asmarkers of the Eos-labile Treg cell
ure S3.
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Figure 4. Help from Reprogrammed Treg Cells Is Required to Support T cell Priming in Antigen-Naive Hosts
(A and B) Foxp3GFP-Cre 3 ROSA26lox-stop-loxDTR mice received CFSE-labeled OT-I and OVA vaccine (day 0), with or without DT depletion on days 2, 1, +1,
and +3. VDLNs were analyzed on day 4. Some groups treated with DT also received rescue with IL-2 (1 ug/dose every 12 hr on days 0–3) and agonist CD40 mAb
(250 ug + 100 ug i.p. days 1 and 3). (A) T cell responses in VDLNs. (B) DC activation (CD86 expression) in VDLNs using the same treatment groups. Panels are
representative of seven experiments, two with rescue.
(C) Prior to Treg cell depletion, Foxp3GFP-Cre 3 ROSA26lox-stop-loxDTR mice were preimmunized with OVA vaccine (prime + boost 3 2), then rechallenged with
CFSE-labeled OT-I readout cells + OVA vaccine, with or without DT depletion. Response in VDLN is shown on day 4. One of two experiments.
(D)Cd40lg/ orWT control mice received adoptive transfer of CFSE-labeled OT-IIRag2/CD4+ effector cells (similar to Figure S4C). SomeCd40lg/ hosts were
rescued by pretransfer of CD40L-sufficient Tregs (Foxp3GFP-Thy1.1), as in Figure 2D. All mice were immunized with cognate peptide for OT-II cells in IFA+CpG,
and responses were measured in VDLNs. One of two experiments. See also Figure S4.
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A Bifunctional Subset of Treg Cellsrequired in order to maintain stable Foxp3 gene expression
during cell division (Zheng et al., 2010). Eos-labile Treg cells
maintained stable Foxp3 protein levels throughout multiple
rounds of cell division (Figure S5A, above), and their Foxp3
expression was stable in lymphopenic hosts (Figure 5C, above).
Thus, the TSDR in Eos-labile Treg cells appeared functionally
active and able to maintain long-term Foxp3 expression.
Taken together, these data were consistent with the hypothe-
sis that Eos-labile Treg cells formed a distinct developmental
subset related to, but not identical with, the Eos-stable subset
and that this distinction emerged as early as the thymus.1006 Immunity 38, 998–1012, May 23, 2013 ª2013 Elsevier Inc.Downregulation of Eos Is Prevented
by Tumor-Induced IDO
Because downregulation of Eos was controlled by specific sig-
nals, we reasoned that there might be opposing signals that
could prevent the loss of Eos. We had previously shown that
the immunoregulatory enzyme indoleamine 2,3-dioxygenase
(IDO) antagonized functional Treg cell reprogramming (Sharma
et al., 2010; Sharma et al., 2009). Therefore, we isolated plasma-
cytoid DCs (pDCs) from tumor-draining LNs (TDLNs), where
many pDCs express high amounts of IDO (Munn et al., 2004),
and tested them in reprogramming assays with resting, naive
Figure 5. The Eos-Labile Cells Are Functional Treg Cells with Stable Foxp3 Expression
(A) Eos-labile (CD38+CD103NEG) and Eos-stable (CD38NEGCD103+) Treg cell populations, and all other nonregulatory CD4+ cells (GFPNEG), were sorted from
spleens of Foxp3GFP donors following 1 hr CHX treatment. mRNA was measured by quantitative RT-PCR and normalized to Gapdh.
(B) Functional suppression assay. Eos-labile and Eos-stable Treg cells were sorted and added to readout T cells + anti-CD3 mitogen, as described in Sup-
plemental Experimental Procedures. Proliferation was measured by thymidine incorporation on day 3.
(C) Rag2/mice received CD4+CD45RBHI effector cells, alone or with sorted Foxp3GFP Treg cell subsets (Eos-labile or Eos-stable). When control mice reached
20% weight loss, all groups were analyzed for histology of colonic mucosa and for Treg cell phenotyping in mesenteric LNs.
(D) Rag2/ mice received adoptive transfer as in (C), and then on day +42 the groups receiving Treg cells were challenged with OT-I + vaccine as shown, and
VDLNs were analyzed for reprogramming.
(A) and (B) are representative of at least three to five independent experiments; (C) and (D) are representative of two experiments each. See also Figure S5.
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A Bifunctional Subset of Treg CellsTreg cells. To block activity of the IDO pathway, we added the
pharmacologic inhibitor 1-methyl-D-tryptophan (1MT) to some
cocultures. Figure 7A shows that when the IDO pathway was
active (no 1MT) the Treg cells were unable to downregulate
Eos and could not undergo reprogramming (middle dot-plot).
When 1MT was added, the same Treg cells now lost Eos and
were able to undergo reprogramming (right-hand dot-plot). The
degree of reprogramming supported by TDLN pDCs was vari-
able, with DCs from more advanced tumors being progressively
more inhibitory for reprogramming. Consistent with a specificeffect of IDO, when pDCs were isolated from TDLNs of Ido1/
mice, these pDCs no longer blocked Treg cell reprogramming
(Figure S7A).
IDO suppressed Treg cell reprogramming in vivo (Figure 7B).
Mice with established B16F10 tumors received tumor-specific
CD8+ pmel-1 cells plus vaccination with cognate hgp100
peptide (Antony et al., 2005). Groups were treated with 1MT in
drinking water or vehicle control. When IDO was active (no
1MT), the Treg cells in TDLNs failed to downregulate Eos after
vaccination and there was no reprogramming. However, whenImmunity 38, 998–1012, May 23, 2013 ª2013 Elsevier Inc. 1007
Figure 6. Eos-Labile Treg Cells Show a Distinct Pattern of DNA Methylation
Cells from thymus or spleen were incubated for 1 hr with CHX, and then GFP+ Treg cells were sorted into Eos-labile (CD38+CD103NEG) and Eos-stable
(CD38NEGCD103+) populations. Control CD4+GFPNEG (other CD4+) cells were sorted from spleen. Genome-wide differential methylation analysis was performed
by using reduced representation bisulfite sequencing (RRBS), as described in Supplemental Experimental Procedures.
(A) Hierarchical clustering analysis and heat map. Rows represent the sample and columns represents the average methylation level (% of methylation) in each
differentially methylated region.
(B) Analysis of DNA methylation for the Foxp3 locus in each population. Average methylation for the Treg-specific demethylation region (TSDR) region (CNS2) is
shown as the superimposed percentage. Tracks (from top to bottom) are as follows: DNA methylation at each CpG site derived from the bisulfite sequencing
reads, RefSeq genes, and conservation score (UCSC genome browser). Red and green colors indicate methylated and unmethylated CpG sites, respectively.
The average methylation values of CpG sites measured are shown next to the TSDR. See also Figure S6.
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A Bifunctional Subset of Treg Cellsmice received 1MT, many Treg cells in TDLNs downregulated
Eos and underwent reprogramming (expressed CD40L, as
shown; and also IL-2 and L17, data not shown).
To test whether Treg cell reprogramming was functionally
important for antitumor T cell responses, we used helper-
deficient Cd40lg/ mice as tumor-bearing hosts and asked
whether adoptive transfer of WT Eos-labile Treg cells could
rescue the activation of pmel-1 effector cells. Pmel-1 cells
were informative in this regard because they are known to1008 Immunity 38, 998–1012, May 23, 2013 ª2013 Elsevier Inc.require CD4+ T cell help for optimal antitumor activity (Antony
et al., 2005). In these studies, all mice received 1MT treatment
so that Treg cells would be able to reprogram if they were
capable of it. Figure 7C shows that only the Eos-labile Treg cells
could undergo reprogramming, express CD40L, and provide
help for pmel-1 priming. Control mice, receiving Eos-stable
Treg cells or nonregulatory CD4+ T cells, showed significantly
impaired pmel-1 activation and antitumor activity (bar graph).
Further, Figure S7B shows that helper activity from Eos-labile
Immunity
A Bifunctional Subset of Treg CellsTreg cells was important to support effective cross-presentation
of endogenous tumor antigens to a new population of antitumor
T cells.
Thus, established tumors actively suppressed Treg cell re-
programming, and amajor mechanism of this effect was attribut-
able to the IDO pathway. Treg reprogramming and antitumor
vaccine responses were impaired in tumor-bearing hosts unless
IDO was blocked.
IDO Activates a Population of Highly-Suppressive
EosHI Treg Cells in TDLNs
In the course of the experiments in Figures 7A and 7B, we noted
that when Treg cells were exposed to IDO, a subpopulation
increased their Eos expression by 5- to 10-fold (the basal, resting
level is indicated by the box in each dot-plot). Cell-sorting
studies in Figure S7C revealed that these new EosHI Treg cells
were derived from the CD103+ (Eos-stable) population. Figures
S7D and S7E show that the EosHI Treg cells corresponded to
the highly suppressive, IDO-activated Treg cells that we have
previously described in TDLNs (Sharma et al., 2007). Thus, not
only did IDO inhibit reprogramming of the Eos-labile subset,
but it also enhanced the suppressive function of the Eos-stable
subset.
IDO Blocks Eos Downregulation via KYN Metabolites
One mechanism by which IDO can affect Treg cells is produc-
tion of kynurenine-pathway (KYN) metabolites, which can
signal through the aryl hydrocarbon receptor (AhR) (Mezrich
et al., 2010). Figure 7D shows that the addition of KYN metab-
olites to cocultures prevented Eos downregulation and blocked
reprogramming, even when the DCs were from VDLNs and did
not express IDO. Pharmacologic-inhibitor studies indicated
that the effect of KYN metabolites was mediated via the AhR
(Figure S7F). STAT3 is a key component of signal transduction
via the IL-6 receptor and has been implicated as a driver
of destabilization of the Treg cell phenotype during inflamma-
tion (Laurence et al., 2012). Figure 7E shows that Treg cells
exposed to reprogramming conditions showed phosphoryla-
tion of STAT3, and this phosphorylation was strongly inhibited
by the addition of KYN metabolites. Figure 7F shows a titration
of a representative KYN metabolite, 3-hydroxyanthranilic acid
(3HAA), demonstrating dose-dependent inhibition of STAT3
phosphorylation. Figure 7G shows that adding excess recom-
binant IL-6 to reprogramming assays progressively increased
STAT3 phosphorylation, and this was antagonized by the pres-
ence of 3HAA (a shift in the ED50 for IL-6 of 1–2 orders of
magnitude). Taken together, these studies supported the
hypothesis that IDO blocked the downregulation of Eos via
KYN metabolites and the AhR and that this effect was medi-
ated at least in part by antagonism of IL-6-induced STAT3
activation.
DISCUSSION
In the current study, we identify a committed subset of reprog-
rammable Treg cells characterized by rapid loss of the core-
pressor Eos in response to specific inflammatory signals. Loss
of Eos allowed a regulated transformation of these Treg cells
into biologically important helper cells, without loss of Foxp3.Developmental commitment to the Eos-labile subset was
evident as early as the thymus and could be distinguished by
characteristic cell-surface markers and DNAmethylation. By us-
ing ablation, adoptive transfer, and gene-depletion approaches,
we show that absence of the Eos-labile Treg cell subset
selectively compromised the ability of naive mice to activate
resting DCs and prime initial T cell responses to new antigen.
Thus, the Eos-labile Treg cell subset supplied an important,
natural helper activity in the immune system.
The Eos-labile cells were authentic Treg cells. Many of them
arose in the thymus; they uniformly expressed Foxp3, CTLA-4,
and CD25, and they were functionally suppressive in vitro and
fully protective in the stringent Rag2/ colitis model. In other
systems, it has been shown that some conventional (nonregula-
tory) CD4+ cells may transiently express Foxp3 following acti-
vation, then later lose this aberrant Foxp3 (Miyao et al., 2012).
However, Eos-labile Treg cells were not these cells, as shown
by the fact that (1) they were present even in thymus (natural
Treg cells) rather than induced by activation, (2) they constitu-
tively expressed Foxp3 even at rest, and (3) Foxp3 expression
was stable and was not lost even after reprogramming.
Because Foxp3 was never lost, our model differed from some
other models in which Treg cells lose expression of Foxp3
(Komatsu et al., 2009; Laurence et al., 2012; Oldenhove et al.,
2009; Zhou et al., 2009). These models often feature prolonged
conditions of pathologic inflammation such as lymphopenia,
sepsis, autoimmunity, or GVHD. In contrast, our studies dealt
with rapid events (hours to days) in the context of mild, natural
immune activation such as vaccination. Under these conditions
Foxp3 was not lost, and the transformation to a proinflammatory
phenotype was instead controlled by Eos.
One key finding was that reprogrammed Treg cells provided
help very rapidly. The Foxp3+ lineage is unique in that many
Treg cells appear constitutively activated and respond more
rapidly than other cells to inflammation (O’Gorman et al.,
2009). We speculate that this property of the Foxp3+ lineage
allows Eos-labile Treg cells to act as ‘‘first responders,’’ deliv-
ering immediate help at a timewhen conventional, nonregulatory
CD4+ cells have not yet had time to activate. If host mice were
preimmunized, and thus had conventional memory CD4+
T cells available, then help from reprogrammed Treg cells was
no longer necessary; but in naive mice encountering a new
antigen, help from reprogrammed Treg cells was critical. The
antigen specificity of Eos-labile Treg cells is not yet known, but
they were present in the thymus, and many thymic-derived
Treg cells recognize self-peptides. Thus, the unique attributes
of Foxp3-lineage cells—hair-trigger responses and constant an-
tigen exposure—may ideally position Eos-labile Treg cells to
deliver rapid help.
However, this raises the paradox of why Treg cells that are
able to reprogram do not lead to autoimmunity. We propose
that autoimmunity is avoided by the strictly local, highly
regulated nature of the reprogramming event. Thus, during
vaccination, reprogramming was confined solely to the VDLNs.
Likewise, in the Rag2/ colitis model, some Eos-labile Treg
cells could be suppressive in the gut even while others were
reprogramming in VDLNs. Thus, Treg cells were allowed to
become helper cells only in specific contexts where permissive
proinflammatory signals already existed.Immunity 38, 998–1012, May 23, 2013 ª2013 Elsevier Inc. 1009
Figure 7. IDO Blocks Eos Downregulation
(A) Plasmacytoid DCs (pDCs) with high IDO expression were obtained by sorting CD11c+ cells from TDLNs of mice with B16F10 tumors and used in
reprogramming cocultures with resting Foxp3GFP Treg cells (from mice without tumors). Cocultures received either no SIINFEKL (‘‘no activation’’ group) or
SIINFEKL (‘‘activated’’ groups), with or without the IDO-pathway inhibitor 1-methyl-D-tryptophan (1MT).
(B) Foxp3GFPmicewith established B16F10 tumorswere treatedwith naive pmel-1 T cells (CD8+, CFSE-labeled) plus hgp100 peptide vaccine in IFA+CpG, with or
without 1MT in drinking water. Panels are representative of five experiments.
(C) Cd40lg/ host mice received preadoptive transfer of sorted Eos-labile or Eos-stable Treg cells from Foxp3GFP mice, all other non-regulatory CD4+ cells,
or no transfer. Then all mice were implanted with B16F10 tumors. After 7 days, mice received pmel-1 + vaccine, with or without 1MT in drinking water. Four days
after vaccination, TDLNs were analyzed and tumor size was measured at necropsy. Pooled data from three identical experiments; *p < .05 by ANOVA, error bars
show SD.
(legend continued on next page)
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A Bifunctional Subset of Treg CellsSimilarly, the DC activating and licensing effect of reprog-
rammed Treg cellsmight appear paradoxical, because Treg cells
normally suppress DCs and keep them in a quiescent state
(Muth et al., 2012). However, this effect is exerted specifically
on resting DCs; once DCs are activated via CD40 ligation, they
become resistant to Treg-mediated suppression (Serra et al.,
2003). Thus, we hypothesize that there exists a balance: sys-
temic inhibition of DCs by suppressive Treg cells in the steady
state, but local activation of DCs by reprogrammed Treg cells
in an acute inflammatory milieu.
Finally, an additional important layer of regulation was pro-
vided by IDO, which blocked the loss of Eos and prevented
Treg cell reprogramming. IDO is involved in immune suppression
and tolerance, so it is logical that it would stabilize the suppres-
sive Treg cell phenotype.We note, however, that in the patholog-
ical setting of tumors this effect became exaggerated, and it
was necessary to pharmacologically inhibit IDO in order for the
Eos-labile Treg cells to successfully reprogram and contribute
their beneficial helper function.
In conclusion, we show that behavior of the corepressor
Eos defines two distinct, committed subsets of Foxp3+ Treg
cells. In certain settings, the natural ‘‘rapid-response’’ role of
Foxp3-lineage cells extends beyond their classical role of sup-
pression and also includes important helper activity mediated
by the Eos-labile subset.
EXPERIMENTAL PROCEDURES
Reagents and Mice
Details of reagents and mouse strains are given in Supplemental Experimental
Procedures. Animal studies were approved by the Institutional Animal Care
and Use Committee of Georgia Health Sciences University.
Tumor, 1MT Administration, and Influenza Infection
Tumor studies were performed as previously described (Sharma et al., 2010).
Tumor area was measured at necropsy on day 11 following dissection. Oral
1MT was administered at 2 mg/ml in drinking water as described (Sharma
et al., 2009). Details of intranasal infection with HKx31 (X31, H3N2) influenza
virus are in Supplemental Experimental Procedures.
Adoptive Transfer and Vaccination
OT-I or pmel-1 spleen cells were enriched by using CD8 magnetic beads
(Miltenyi Biotech) and 2 3 106 cells injected intravenously (i.v.). For Treg
cell sorting, thymus or spleen from Foxp3GFP mice (Fontenot et al., 2005)
were preincubated in vitro for 1 hr with CHX (20 ug/ml) and then stained
with CD103 versus CD38 and sorted by MoFlo cell-sorter with doublet
discrimination. Treg cells (1 3 105 cells unless otherwise indicated) or nonre-
gulatory CD4+ cells (CD4+GFP, 1 3 106 cells) were injected i.v. Vaccines
comprised whole OVA protein or hgp100 peptide plus CpG-1826 in IFA (see
Supplemental Experimental Procedures) administered in the footpad and
popliteal LNs harvested after 4 days. For DTR experiments, mice received
DT 1 ug/dose intraperitoneally (i.p.).
FACS Staining
Details of all staining protocols are in Supplemental Experimental Procedures
available online.(D) DCs from VDLNs (prepared as in Figure 1C), which have low IDO expression, w
mixture as described in Supplemental Experimental Procedures.
(E–G) Treg cells were incubated for 18 hr in reprogramming cocultures as in (D), a
KYN metabolites. (F) shows the dose response for 3-hydroxyanthranilic acid (3
staining positive for pSTAT3 is shown. (G) shows response of pSTAT3 to exogen
Each panel is representative of at least three experiments or as noted. See alsoEos Transduction
Mouse Eoswas cloned into the pMIG plasmid to form a bicistronicMSCV-Eos-
ires-GFP vector and expressed in 293T cells by using pCL-Eco (Imgenex)
packaging plasmid. Control (GFP-only) virus used empty pMIG vector (Addg-
ene). These viruses were used to transduce Treg cells in cocultures, as
described in Supplemental Experimental Procedures.
Methylation Analysis
Methylation analysis of genomic DNA by reduced representation bisulfite
sequencing (RRBS) is described in detail in Supplemental Experimental
Procedures. The raw and analyzed sequencing data have been submitted to
NCBI Gene Expression Omnibus (GEO) database.
Statistical Analysis
Multiple treatment groups were compared by ANOVA with Tukey’s HSD test.
ACCESSION NUMBERS
The raw and analyzed sequencing data have been submitted to NCBI Gene
Expression Omnibus (GEO) database under accession number GSE44380.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2013.01.013.
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